In-Vitro Lymphoid Cell Clusters for Human Immune Response Modeling

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for studying adaptive immunity, such as inbred mouse studies, lack a system that replicates key features like affinity maturation and class switching, making it difficult to understand human vaccine responses effectively.

Innovation Solution

An in-vitro cell cluster comprising lymphoid cells with a germinal center and T-cells is developed, capable of maintaining a functional organization for at least 24 hours, which can be modulated by adjuvants and exposed to antigens to simulate immune responses, including antibody production and affinity maturation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If inbred mouse studies are used to study adaptive immunity, then a wealth of information about immune mechanisms can be obtained, but the system fails to replicate key features like affinity maturation and class switching, making it difficult to predict human vaccine responses

Engineering Contradiction:
Improvepredictive value for human vaccine responsesVSAvoidability to replicate key immune features like affinity maturation and class switching
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent creates an in vitro organotypic system that copies the essential structural and functional features of human lymphoid organs, including germinal centers with follicular dendritic cells, B cells, and T cells. This human-based model system replicates key immune processes like affinity maturation and class switching that were missing in mouse models, thereby improving predictive value for human vaccine responses while maintaining the versatility to study multiple aspects of adaptive immunity

Inventive Principle:
Principle #26Copying

2Adaptability or versatility

If complex in vivo mouse models are used to study adaptive immunity, then comprehensive immune responses can be observed, but the methods are difficult or impossible to confirm in humans and show poor predictive value

Engineering Contradiction:
Improvecomprehensive observation of immune responsesVSAvoidpredictive value for human responses
Core Design Contradiction:
Adaptability or versatilityVSReliability

Solution Approach 1:

The patent transitions from in vivo mouse models to an in vitro human-based organotypic system, changing the fundamental parameters of the model system. By using human lymphoid cells and maintaining human-specific immune processes like affinity maturation and class switching in culture, the system achieves both comprehensive observation capabilities and high predictive value for human responses

Inventive Principle:
Principle #35Parameter changes

3Loss of information

If traditional in vivo studies are used, then important information about immune mechanisms can be obtained, but many mechanistic aspects remain inaccessible due to lack of systems that replicate affinity maturation and class switching

Engineering Contradiction:
Improveaccessibility of mechanistic informationVSAvoidreplication of affinity maturation and class switching
Core Design Contradiction:
Loss of informationVSAdaptability or versatility

Solution Approach 1:

The in vitro organotypic system is designed to self-organize and replicate human lymphoid architecture spontaneously when human lymphoid cells are cultured under appropriate conditions. The system autonomously develops germinal centers, follicular dendritic cell networks, and functional zones without requiring complex external manipulation, thereby making mechanistic information accessible while maintaining the ability to replicate affinity maturation and class switching

Inventive Principle:
Principle #25Self-service

Data Source

PatentUS20230235284A1Systems and methods to model adaptive immune responses
Publication Date: 2023.07.27 THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
  • US20230235284A1 patent drawing
  • US20230235284A1 patent drawing
  • US20230235284A1 patent drawing

AI summary

Disclosed herein are methods, systems and devices to model adaptive immune responses and develop and/or test improved antibodies, vaccines, and other therapeutic agents. The adaptive immune responses can be modeled using lymphoid tissue derived from a subject.